The Growing Problem of New Psychoactive Substances (NPS)

Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 32)


The term “new psychoactive substances” (NPS) can be defined as individual drugs in pure form or in complex preparations that are not scheduled under the Single Convention on Narcotic Drugs (1961) or the Convention on Psychotropic Substances (1971). NPS may be categorized by chemical structure, by psychoactive properties, by biological targets, or by source (plant, synthetic, or combined). The emergence of hundreds of NPS in the past decade is challenging for public health and drug policies globally. The novelty of NPS, their ambiguous legal status, ability to evade toxicological tests, swift adaptation to legal restrictions, global Internet marketing, and scant public knowledge of their adverse effects are among the key drivers of this twenty-first century phenomenon. Multi-disciplinary research in areas of biology, epidemiology, prevention, and web analytics are needed to develop effective responses in a domain capable of overwhelming current international conventions and national drug control policies. Ultimately, research-guided prevention education will fortify societies against this tidal wave.


Cathinones New psychoactive substances Synthetic cannabinoids 


  1. 1.
    Nichols DE, Fantegrossi WE (2013) Emerging designer drugs. In: Madras B, Kuhar M (eds) The effects of drug abuse on the human nervous system. Academic Press, Cambridge, MA, pp 575–596Google Scholar
  2. 2.
    Papaseit E, Farré M, Schifano F, Torrens M (2014) Emerging drugs in Europe. Curr Opin Psychiatry 27:243–250CrossRefPubMedGoogle Scholar
  3. 3.
    Deluca P, Davey Z, Corazza O et al (2012) Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry 39:221–226CrossRefPubMedGoogle Scholar
  4. 4.
    Brandt SD, King LA, Evans-Brown M (2014) The new drug phenomenon. Drug Test Anal 6:587–597CrossRefPubMedGoogle Scholar
  5. 5.
    Bonar EE, Ashrafioun L, Ilgen MA (2014) Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates. Drug Alcohol Depend 143:268–271CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
  7. 7.
  8. 8.
    Madras BK, Fahey MA, Goulet M et al (2006) Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. J Pharmacol Exp Ther 319:570–585CrossRefPubMedGoogle Scholar
  9. 9.
    Meltzer PC, Butler D, Deschamps JR, Madras BK (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49:1420–1432CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
  11. 11.
    DEA (2014) Special report: synthetic cannabinoids and cathinones reported in NFLIS, 2010–2013.
  12. 12.
    Wood DM, Greene SL, Dargan PI (2013) Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: mephedrone (4-methylmethcathinone) control appears to be effective using this model. Emerg Med J 30:70–71CrossRefPubMedGoogle Scholar
  13. 13.
    EMCDDA (2015) New psychoactive substances in Europe: an update from the EU Early Warning System March 2015.
  14. 14.
    EMCDDA (2015) European Drug Report 2015: trends and developments.
  15. 15.
  16. 16.
    EMCDDA EU Early Warning System (2015) New psychoactive substances in Europe: an update from the EU early warning system March 2015.
  17. 17.
    UNODC: United Nations Office of Drugs and Crime (2015) World Drug Report 2015.
  18. 18.
  19. 19.
    Johnston LD, O’Malley PM, Miech RA et al (2016) Monitoring the future national results on adolescent drug use: overview of key findings, 2015. Institute for Social Research, the University of Michigan, Ann Arbor, MIGoogle Scholar
  20. 20.
    Trecki J, Gerona RR, Schwartz MD (2015) Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373:103–107Google Scholar
  21. 21.
    Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980CrossRefPubMedGoogle Scholar
  22. 22.
    Bonnet C, Rusz J, Megrelishvili M et al (2014) Eye movements in ephedrone-induced parkinsonism. PLoS One 9, e104784CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Schneir A, Ly BT, Casagrande K et al (2014) Comprehensive analysis of “bath salts” purchased from California stores and the internet. Clin Toxicol (Phila) 52:651–658CrossRefGoogle Scholar
  24. 24.
    Seely KA, Patton AL, Moran CL et al (2013) Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int 233:416–422CrossRefPubMedGoogle Scholar
  25. 25.
    Carhart-Harris RL, King LA, Nutt DJ (2011) A web-based survey on mephedrone. Drug Alcohol Depend 118:19–22CrossRefPubMedGoogle Scholar
  26. 26.
    Corazza O, Assi S, Simonato P et al (2013) Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project. Hum Psychopharmacol 28:317–323CrossRefPubMedGoogle Scholar
  27. 27.
    Baumann MH, Solis E Jr, Watterson LR et al (2014) Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci 34:15150–15158CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Fass JA, Fass AD, Garcia AS (2012) Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann Pharmacother 46:436–441CrossRefPubMedGoogle Scholar
  29. 29.
    Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33–42CrossRefPubMedGoogle Scholar
  30. 30.
  31. 31.
    Castaneto MS, Gorelick DA, Desrosiers NA et al (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41CrossRefPubMedGoogle Scholar
  32. 32.
    Gunderson EW, Haughey HM, Ait-Daoud N et al (2012) “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 21:320–326CrossRefPubMedGoogle Scholar
  33. 33.
    Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39:234–243CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hermanns-Clausen M, Kithinji J, Spehl M et al (2016) Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project. Drug Test Anal 2016 [Epub ahead of print]Google Scholar
  35. 35.
    Tait RJ, Caldicott D, Mountain D et al (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 54:1–13CrossRefGoogle Scholar
  36. 36.
    Zawilska JB, Andrzejczak D (2015) Next generation of novel psychoactive substances on the horizon - A complex problem to face. Drug Alcohol Depend 157:1–17CrossRefPubMedGoogle Scholar
  37. 37.
    Coviello L, Sohn Y, Kramer AD et al (2014) Detecting emotional contagion in massive social networks. PLoS One 12;9(3):e90315Google Scholar
  38. 38.
    Kim DA, Hwong AR, Stafford D, Hughes et al (2015) Social network targeting to maximise population behaviour change: a cluster randomised controlled trial. Lancet 386:145–153Google Scholar
  39. 39.
    Shakya HB, Christakis NA, Fowler JH (2012) Parental influence on substance use in adolescent social networks. Arch Pediatr Adolesc Med 166:1132–1139CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
  41. 41.
    King LA, Ujváry I, Brandt SD (2014) Drug laws and the ‘derivative’ problem. Drug Test Anal 7–8:879–883CrossRefGoogle Scholar
  42. 42.
    Jensen NH, Roth BL (2008) Massively parallel screening of the receptorome. Comb Chem High Throughput Screen 11:420–426CrossRefPubMedGoogle Scholar
  43. 43.
    Sheffler DJ, Roth BL (2003) Salvinorin A: the “magic mint” hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24:107–109CrossRefPubMedGoogle Scholar
  44. 44.
    Setola V, Roth BL (2005) Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on ‘fen-phen’. Expert Opin Drug Metab Toxicol 1:377–387CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Harvard Medical School, Department of PsychiatryBostonUSA
  2. 2.Division of Alcohol and Drug Abuse, McLean HospitalBelmontUSA

Personalised recommendations